The global Nucleic Acid Amplification Testing Market was valued at USD 7.3 Billion in 2022 and it is anticipated to grow up to USD 24.5 Billion by 2032, at a CAGR of 12.8% during the forecast period.

Know More- https://www.globalinsightservices.com/reports/nucleic-acid-amplification-testing-market/

A Nucleic Acid Amplification Test, or NAAT, is a type of viral diagnostic test for SARS-CoV-2, the virus that causes COVID-19. NAATs detect genetic material (nucleic acids). NAATs for SARS-CoV-2 specifically identify the RNA (ribonucleic acid) sequences that comprise the genetic material of the virus.


Major Players in the Global Nucleic Acid Amplification Testing Market

The key players in the Nucleic Acid Amplification Testing Market F. Hoffmann-La Roche Ltd; Becton, Dickinson and Company; Danaher Corporation; Abbott Laboratories; Illumina, Inc.; Siemens Healthineers; bio Mérieux SA; Novartis AG; Bio-Rad Laboratories, Inc., See gene Inc., among others.